Oligonucleotide-based molecular therapy for restenosis after angioplasty

被引：2

作者：

Aoki, M

Morishita, R

Ogihara, T

机构：

[1] Osaka Univ, Grad Sch Med, Dept Geriatr Med, Suita, Osaka 5650871, Japan

[2] Osaka Univ, Grad Sch Med, Div Clin Gene Therapy, Suita, Osaka 5650871, Japan

来源：

CURRENT DRUG TARGETS | 2003年 / 4卷 / 08期

关键词：

gene therapy; antisense; ribozyme; cis-element decoy; restenosis; E2F; NFkB;

D O I：

10.2174/1389450033490830

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Molecular therapy is emerging as a potential strategy for the treatment of cardiovascular disease such as restenosis after angioplasty, vascular bypass graft occlusion, transplant coronary vasculopathy, homozygous familial hypercholesterolemia and cystic fibrosis, for which no known effective therapy exists. Molecular biology and pathophysiology of the cardiovascular system have started to emerge, and the time is ripe for the introduction of gene therapy to the management of cardiovascular disorders. In this review, we have focused on the future potential of oligonucleotide-based gene therapy for restenosis after angioplasty, which still remains an issue in the field of cardiovascular disease.

引用

页码：613 / 618

页数：6

共 43 条

[1] Endothelial apoptosis induced by oxidative stress through activation of NF-κB -: Antiapoptotic effect of antioxidant agents on endothelial cells [J].